Taysha Gene Therapies Provides Inducement Grants for New Hires
DALLAS — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a pioneering clinical-stage biotechnology company, has made significant strides in the realm of gene therapies focused on treating severe monogenic diseases affecting the central nervous system. Recently, the company's Compensation Committee extended an inducement grant to three new employees, representing an important milestone in Taysha's growth strategy.
Details of the Inducement Grant
On a recent date, Taysha granted options to purchase a total of 157,000 shares of the Company’s common stock to these new team members. The stock options are integral to the Taysha Gene Therapies, Inc. 2023 Inducement Plan. This plan serves as a key component of Taysha's strategy to attract and retain top talent in the competitive biotechnology sector, particularly for roles critical to advancing innovative therapies.
Stock Option Structure
The stock options come with an exercise price of $1.53 per share, directly correlating to the Company’s closing stock price on the grant date. Importantly, these options have a 10-year validity period. Vesting is structured to be gradual, with 25% vesting after the first year of service, and the balance vesting in equal monthly installments over the subsequent three years. Continued employment with Taysha is essential for the vesting of these stock options.
About Taysha Gene Therapies
Taysha Gene Therapies specializes in developing adeno-associated virus (AAV)-based gene therapies aimed specifically at severe monogenic neurological disorders. The Company leads the charge with its flagship program, TSHA-102, targeting Rett syndrome — an often devastating condition that currently lacks effective treatment options addressing its genetic basis. Taysha’s commitment is to revolutionize the treatment landscape for patients and families grappling with such serious conditions.
Focus on Transformative Medicine
With a clear vision to create impactful therapies, Taysha Gene Therapies is dedicated to addressing substantial medical needs. The Company's management team comes with a wealth of experience in gene therapy development and commercialization, propelling Taysha toward its goal of translating innovative treatments from the laboratory to real-world applications. Leveraging its knowledge, the company combines advanced manufacturing processes with proven AAV9 technology to expedite this transition.
Company Contacts
If you would like to learn more about Taysha Gene Therapies, please reach out to their team. For corporate communications and investor relations, contact Hayleigh Collins, who serves as the Director and Head of Corporate Communications at Taysha. She is available to provide insights regarding the Company, its operations, and its promising future in the gene therapy sector.
Media Inquiries
For media-related questions or discussions, you can reach out to Carolyn Hawley with Inizio Evoke. Her team is well-equipped to engage with the press and provide more information about Taysha Gene Therapies and its pivotal role in advancing healthcare solutions.
Frequently Asked Questions
What is Taysha Gene Therapies?
Taysha Gene Therapies, Inc. is a biotechnology company focused on developing advanced gene therapies for severe diseases affecting the central nervous system.
What are the stock options granted by Taysha for?
The stock options are intended to attract and retain talented individuals to contribute to the Company's mission in gene therapy.
What is the significance of the 2023 Inducement Plan?
The 2023 Inducement Plan aims to provide incentives for new hires, which is a crucial part of Taysha's growth strategy.
Who do I contact for more information about Taysha?
You can contact Hayleigh Collins for corporate communications or Carolyn Hawley for media inquiries regarding Taysha Gene Therapies.
What is TSHA’s lead product candidate?
TSHA-102 is Taysha’s lead product candidate targeting Rett syndrome, a rare disorder requiring effective treatment options.
